United Therapeutics CEO Exercises Options and Sells $5.2M in Stock Under 10b5-1 Plan

Insider Transaction Analysis: United Therapeutics Corp (NASDAQ: UTHR)

Summary

On October 7, 2026, Chairperson & CEO Martine A. Rothblatt executed a series of transactions involving the exercise of stock options and the subsequent sale of 9,500 shares of United Therapeutics Common Stock held indirectly by trust. The shares were sold at weighted average prices ranging from $542.73 to $556.48, resulting in total gross proceeds of approximately $5.21 million.

Key Details

• Nature of Transactions:
  • Exercised 9,500 stock options expiring March 15, 2027, at an exercise price of $117.76 per share.
  • Disposed of all 9,500 underlying shares via 13 open-market block sales at an average realized price of roughly $548.94 per share.
• Pre-Arranged Plan: Transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.
• Post-Transaction Holdings: The trust retains 324,443 shares of Common Stock and 280,910 unexercised options expiring in March 2027. Dr. Rothblatt also holds 40,513 shares directly and over 300,000 shares across other family trusts and spouse holdings.

Market & Investor Context

Because this transaction represents a standard cashless option exercise and programmed sale under a pre-established Rule 10b5-1 trading plan scheduled to expire in late 2026/early 2027, it carries low informational impact regarding insider sentiment or operational performance.